ArticleFrontiers in immunology
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.
Article in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?Multiple sclerosis and related disorders · 2022Pooled it
- A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.Dermatologic therapy · 2022Pooled it
- SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2022Pooled it
- Interleukin in Immune-Mediated Diseases: An Updated Review.Molecular biotechnology · 2025Review
- Is There a Correlation Between Periodontal Disease Symptoms and the COVID-19 Vaccination?Cureus · 2024Article
- Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response.Nanotheranostics · 2024Review
- Retinal artery occlusion following CoronaVac injection in a 45-year-old Filipino.GMS ophthalmology cases · 2023Article
- Review
- Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.Journal of cosmetic dermatology · 2022Article
- Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases.Pediatric rheumatology online journal · 2022Article
- Cutaneous findings following COVID-19 vaccination: review of world literature and own experience.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Review
- Multiple evanescent white dot syndrome (MEWDS) following inactivated COVID-19 vaccination (Sinovac-CoronaVac).Arquivos brasileiros de oftalmologia · 2022Article
- Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.Frontiers in microbiology · 2022Review
- Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.The British journal of dermatology · 2022Article
- Multiple Sclerosis, COVID-19 and Vaccines: Making the Point.Neurology and therapy · 2021Review
- COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis.Rheumatology international · 2021Review
- Review
- Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination.Journal of ophthalmic inflammation and infection · 2021Article
- The challenges of the pandemic and the vaccination against covid-19 in pediatric patients with kidney disease.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.